BIND BIOSCIENCES






High-Precision Therapeutics through Medicinal Nanoengineering®

Executive Summary

- Medicinal Nanoengineering® enables enhanced trafficking of drugs to tumors, resulting in better efficacy and therapeutic index
- Demonstrated to improve TI of cytotoxic agents and molecularly targeted cancer drugs
- Physicochemical and biopharmaceutical properties of many oncology compounds (marketed and developmental) are extremely compatible with the BIND platform

BIND BIOSCIENCES

BIND Medicinal Nanoengineering platform

BIND Targeted Nanoparticle



- Controlled release polymers
- API
- Stealth and protective layer
- Targeting ligand

Features

High drug concentrations in target tissues
- Long circulating half-life
- Tunable biodistribution
- Immune system evasion
- Dual targeting mechanisms

Unmodified API

Wide range of APIs

FDA approved, biocompatible, biodegradable polymers

Robust, reproducible and scalable manufacturing

Best in class Drugs

Expanded Therapeutic Index

Enabling of Difficult APIs

Expanded Indications and Lifecycle

High Barriers to Generics

Clear Regulatory Path

Low COGS

BIND BIOSCIENCES

Our first clinical stage product: BIND-014

- **BIND-014 goal: Best-in-class taxane**
- **Target:** PSMA
  - Clinically validated target with widespread solid tumor expression
  - Prostate cancer cell surface (95% of patients)
  - Non-prostate solid tumor neovasculature (> 80% of breast, colorectal, renal and bladder cancer patients)



- **Payload:** Docetaxel
  - Approved for prostate, breast, lung, gastric, and head/neck cancers
- **Development pathway**
  - Well-defined 505(b)(2) registration pathway
  - Ongoing Phase 1 clinical study in solid tumors

BIND BIOSCIENCES

BIND-014 and Taxotere PK









BIND-014 and Taxotere tumor targeting





BIND-014 efficacy and tolerability









BIND-014 Phase 1 clinical study

- **BIND-014-001**
  - A Phase 1 Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014, Given by IV Infusion to Patients with Advanced or Metastatic Cancer
- **Investigators**: Dan Von Hoff (Tgen), Pat LoRusso (Karmanos), Peter Eisenberg (Marin Cancer Center)
- **Primary objective**
  - Assess the dose limiting toxicities of BIND-014, determine the maximum tolerated dose when given once every three weeks, and select a dose for use in Phase 2 clinical studies
- **Secondary objectives**
  - Characterize the PK profile of BIND-014
  - Assess any preliminary evidence of anti-tumor activity

BIND BIOSCIENCES

Medicinal nanoengineering of partner kinase inhibitor

In vitro release



PK in rats



Enhanced tumor accumulation



Efficacy at lower dose



BIND Medicinal Nanoengineering platform



BIND overview

BIND was founded in 2006 by two pioneering academic investigators…

Robert Langer, ScD – MIT, David H. Koch Institute Professor

Omid Farokhzad, MD – Harvard Medical School, Associate Professor

…is led by an experienced team of successful entrepreneurs and drug developers…

Scott Minick – President & CEO
ARCH Venture Partners, SEQUUS, Baxter, Lilly

Jeff Hrkach, PhD – SVP, Pharm Sci
Momenta, Alkermes, AIR

Jim Wright, PhD – CSO
Infinity, Millennium, Alkermes, BI

Steve Zale, PhD – VP, Development
Alkermes, Sepracor

Ed Schnipper, MD – CMO
ALZA, SEQUUS, Roche

Paul Burgess, JD – VP, IP
J&J, TransForm, Genetics Institute

Andrea Franz – CFO
Franz Assoc., ESS, Groundwater Technologies

Dan Koerwer – Head, Market & Bus. Dev.
Eidetica Biopharma, Biogen Idec

…and has been backed by leading VC firms and US government

BIND high-precision therapeutics through Medicinal Nanoengineering

TR50

MIT Technology Review 2010
50 Most Innovative Companies

The 50 Most Innovative Companies 2011

MIT Technology Review 2011
50 Most Innovative Companies

THE WALL STREET JOURNAL.
WEDNESDAY, SEPTEMBER 12, 2007

Betting on Nanotech Therapies

2011 EDISON AWARDS
INNOVATIONS & INNOVATORS

Nanotech Briefs Nano50

HIGH TECH ALL-STARS
MIT
14th Annual

Fierce 15 WINNER
FierceBiotech

SCIENTIFIC AMERICAN worldVIEW

Magic Nano-Bullets

Advances in nanotechnology could make drug delivery far more accurate and effective

THE TIMES

Cancer treatment dodges immune system